Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry

Published:2016-10 Issue: Volume:1033-1034 Page:117-127
ISSN:1570-0232
Container-title:Journal of Chromatography B
language:en
Short-container-title:Journal of Chromatography B

Author:

Zhu Yunting,Li Liang,Zhang Ge,Wan Hong,Yang Changyong,Diao Xingxing,Chen Xiaoyan,Zhang Lianshan,Zhong Dafang

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry

Reference28 articles.

1. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer;Eroglu;Oncologist,2014

2. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1cm or smaller;Gonzalez-Angulo;J. Clin. Oncol.,2009

3. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009

4. HER2-directed therapy: current treatment options for HER2-positive breast cancer;Ahmed;Breast Cancer,2015

5. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development;Singh;Br. J. Cancer,2014

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Electro-Activated Dissociation Fragmentation Technique to Identifying Glucuronidation and Oxidative Metabolism Sites of Vepdegestrant by Liquid Chromatography-High Resolution Mass Spectrometry;Drug Metabolism and Disposition;2024-06-03

2. Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases;Drug Design, Development and Therapy;2024-03

3. HER2⁺ advanced gastric cancer: Current state and opportunities (Review);International Journal of Oncology;2024-02-19

4. Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients;Therapeutic Advances in Medical Oncology;2024-01

5. Targeted multimodal synergistic therapy of drug-resistant HER2-positive breast cancer by pyrotinib-ICG self-assembled nanoparticles;American Journal of Cancer Research;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3